The Viz Oncology Suite with NCCN Guidelines delivers personalized, guideline-directed recommendations at the point of care
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced an agreement with the National Comprehensive Cancer Network. This collaboration integrates NCCN Clinical Practice Guidelines in Oncology for Breast, Prostate, and Bladder Cancer into the Viz Oncology Platform making this important information readily available to clinicians when they’re making critical decisions about patient care. Through this collaboration, the Viz Oncology platform will leverage NCCN’s authoritative guidelines to compare real-time patient data against evidence-based best practices. This will help oncologists identify missing tests, ensuring guideline-directed care options are identified efficiently, and streamlining treatment planning across multidisciplinary oncology teams.
Health Technology Insights: NeuraLight Unveils Scientific Leaders Advancing Neurology
The Viz Oncology Suite is a clinical decision support system that integrates seamlessly with the electronic health record to aggregate and summarize patient data, flag missing tests, and provide recommendations aligned with NCCN Guidelines. By connecting patient data directly to NCCN Guidelines, Viz Oncology has the potential to help oncologists work more efficiently and spend less time manually reconciling information across systems. By surfacing the most relevant insights and guideline-based treatment options in real time, the platform enables oncologists to focus on patient care rather than manual chart review and data reconciliation.
“Our mission at NCCN is to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives,” said Crystal S. Denlinger, MD, Chief Executive Officer of NCCN. “The collaboration with Viz Oncology places the evidence-based, expert consensus-driven NCCN Guidelines into a platform that helps oncologists provide guideline-concordant care efficiently in order to improve outcomes.”
The NCCN Guidelines are the most widely used and respected clinical practice recommendations in oncology, representing the consensus of leading cancer centers on the optimal management of more than 97% of cancer cases. By integrating this content, Viz Oncology provides oncologists with trusted, guideline-based context to inform treatment decisions, improve consistency, and reduce variability in care.
“Oncology care has become increasingly complex, with evolving biomarkers, therapies, and combinations that demand constant awareness to offer patients access to the full set of effective treatment options,” said Tim Showalter, MD, Chief Medical Officer at Viz.ai. “By combining Viz Oncology’s capabilities with NCCN’s gold-standard guidelines, we’re giving clinicians an unprecedented ability to deliver efficient, evidence-based, and personalized cancer care.”
Health Technology Insights: Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
